2 brilliant growth shares I’d buy in July

Royston Wild looks at two stocks with white-hot growth prospects.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

EKF Diagnostics (LSE: EKF) was setting the pace in Thursday business following the release of terrific trading details.

The medical play was last 8% higher on the day after hitting two-and-a-half-year peaks of 26p per share earlier in the session.

EKF announced that “trading in the second quarter of the year has continued the favourable trends experienced in the first quarter,” adding that Junes sales had been particularly strong. The Cardiff business said that this “is entirely due to organic growth with no major tenders won during the period.”

As a result, the AIM-listed firm advised that adjusted EBITDA for 2017 should ring in “comfortably ahead” of current projections.

And to round off a perky announcement, the blood testing star declared that, as a result of strong cash generation, that net cash as of June 30 stood at £4m. This is a vast upgrade from net cash of £2.2m posted at the end of 2016.

Set to bounce?

The City had already been predicting strong bottom-line growth prior to today’s release, forecasts pointing to pre-tax profit of £3.6m versus last year’s £1m loss. And profits were expected to tip to £4m in 2018.

But today’s release is likely to lead to seismic upgrades to these numbers in the near term. And further upward revisions are very likely should EKF keep up the momentum. As such, I reckon the stock is a great pick despite its conventionally-high forward P/E ratio of 31.3 times.

A champion boxer

DS Smith (LSE: SMDS) is another London growth giant that investors should take a close look at.

The company has proven to be a reliable growth generator for some years now, and the number crunchers expect further expansion of 3% and 6% in 2017 and 2018 respectively. These figures also make it decent value for money, sporting a prospective P/E rating of just 14.5 times.

The box-builder’s stock value also exploded recently after the release of perky financials, the London business gaining fuel after last week’s full-year results and striding to fresh record peaks above 485p per share just today.

DS Smith declared that revenues detonated 18% in 2016, to £4.9bn, a result that powered adjusted pre-tax profit 18% higher to £391m. While sterling weakness gave the top line a welcome boost, this does not tell the whole story as sales at constant currencies still rose by a healthy 6% year-on-year.

The packager’s programme of spreading its wingspan across the continent continues to pay off handsomely. It noted “continued excellent growth from pan-European customers” and enjoyed growth in all of its regions last year.

DS Smith shelled out £85m on acquisitions last year alone, and its appetite for M&A shows no signs of waning. The company has also bought an 80% stake in Interstate Resources this month for £722m, with an option to buy the remaining share within five years, in a move that marks its first foray into the massive US market.

I am confident the huge investment it is making to bolster its global footprint and position in key growth areas should continue to deliver meaty earnings growth in the years ahead.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended DS Smith. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian man making doubtful face at camera
Investing Articles

£10,000 invested in Tesla stock a fortnight ago is now worth…

Some retail investors have been trying to catch a falling knife with Tesla stock, but many have had their fingers…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

If a 30-year-old puts £400 a month in the stock market, here’s what they could retire on

Many Britons don’t leverage the stock market to build wealth, and I think that’s a mistake. Here’s how to do…

Read more »

Black father and two young daughters dancing at home
Investing Articles

Just released: our 3 top small-cap stocks to consider buying in March [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

Shock news: the FTSE 100 is beating the S&P 500 and Nasdaq over one year!

Quite suddenly, the UK's FTSE 100 index has surged past the S&P 500 and Nasdaq Composite, beating both over one…

Read more »

Investing Articles

I asked ChatGPT to name 5 UK stocks for a perfectly balanced ISA – here’s what it picked! 

Harvey Jones is looking for UK stocks to add to this year's ISA, and decided to call in some assistance…

Read more »

Dividend Shares

With a 13.66% yield, is the FTSE 250’s largest dividend worth considering?

Jon Smith eyes up the highest yielding stock in the FTSE 250 at the moment, and balances out the risks…

Read more »

Investing Articles

Down 22%! Is this my chance to buy Nvidia stock?

Ben McPoland weighs up the case for and the case against reintroducing AI chip king Nvidia into his Stocks and…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Down 34%, are Greggs shares now a bargain?

Christopher Ruane looks at some pros and cons of buying Greggs' shares after the baker's valuation has taken a tumble…

Read more »